TY - JOUR
T1 - Efficacy of erythropoietin as a neuroprotective agent in CKD-associated cognitive dysfunction
T2 - A literature systematic review
AU - Barbieri, Michelangela
AU - Chiodini, Paolo
AU - Di Gennaro, Piergiacomo
AU - Hafez, Gaye
AU - Liabeuf, Sophie
AU - Malyszko, Jolanta
AU - Mani, Laila Yasmin
AU - Raso, Francesco Mattace
AU - Pepin, Marion
AU - Perico, Norberto
AU - Simeoni, Mariadelina
AU - Zoccali, Carmine
AU - Tortorella, Giovanni
AU - Capuano, Annalisa
AU - Remuzzi, Giuseppe
AU - Capasso, Giovambattista
AU - Paolisso, Giuseppe
N1 - Publisher Copyright: © 2024
PY - 2024/5
Y1 - 2024/5
N2 - Patients with chronic kidney disease (CKD) often experience mild cognitive impairment and other neurocognitive disorders. Studies have shown that erythropoietin (EPO) and its receptor have neuroprotective effects in cell and animal models of nervous system disorders. Recombinant human EPO (rHuEPO), commonly used to treat anemia in CKD patients, could be a neuroprotective agent. In this systematic review, we aimed to assess the published studies investigating the cognitive benefits of rHuEPO treatment in individuals with reduced kidney function. We comprehensively searched Pubmed, Cochrane Library, Scopus, and Web of Science databases from 1990 to 2023. After selection, 24 studies were analyzed, considering study design, sample size, participant characteristics, intervention, and main findings. The collective results of these studies in CKD patients indicated that rHuEPO enhances brain function, improves performance on neuropsychological tests, and positively affects electroencephalography measurements. These findings suggest that rHuEPO could be a promising neuroprotective agent for managing CKD-related cognitive impairment.
AB - Patients with chronic kidney disease (CKD) often experience mild cognitive impairment and other neurocognitive disorders. Studies have shown that erythropoietin (EPO) and its receptor have neuroprotective effects in cell and animal models of nervous system disorders. Recombinant human EPO (rHuEPO), commonly used to treat anemia in CKD patients, could be a neuroprotective agent. In this systematic review, we aimed to assess the published studies investigating the cognitive benefits of rHuEPO treatment in individuals with reduced kidney function. We comprehensively searched Pubmed, Cochrane Library, Scopus, and Web of Science databases from 1990 to 2023. After selection, 24 studies were analyzed, considering study design, sample size, participant characteristics, intervention, and main findings. The collective results of these studies in CKD patients indicated that rHuEPO enhances brain function, improves performance on neuropsychological tests, and positively affects electroencephalography measurements. These findings suggest that rHuEPO could be a promising neuroprotective agent for managing CKD-related cognitive impairment.
UR - http://www.scopus.com/inward/record.url?scp=85188142825&partnerID=8YFLogxK
U2 - 10.1016/j.phrs.2024.107146
DO - 10.1016/j.phrs.2024.107146
M3 - Review article
C2 - 38493928
AN - SCOPUS:85188142825
SN - 1043-6618
VL - 203
JO - Pharmacological Research
JF - Pharmacological Research
M1 - 107146
ER -